Kidney function after nonmyeloablative hematopoietic cell transplant for sickle cell disease.

ABSTRACT: Hematopoietic cell transplantation (HCT) is potentially curative for patients with sickle cell disease (SCD). Both SCD and HCT cause kidney damage. This study analyzed data from 160 patients who received nonmyelablative HCT for SCD. Renal function was assessed at baseline and annually for 3years. The rate of new-onset eGFR <60 ml/min/1.73m² was low (2.8%). Rapid kidney function decline in the first year post-HCT was noted in 7.5% of patients but was not associated with subsequently worse renal function. The eGFR decreased post-HCT (1 year: -7.19 p < 0.0001, 2 year: -11.32 p < 0.0001, 3 year: -12.37 ml/min/1.73m² p < 0.0001). Mean eGFR remained within normal limits throughout the follow-up period (1 year:119, 2 year:115, 3 year:113 ml/min/1.73m²). Hyperfiltr

SUBMITTER: Limerick E 

PROVIDER: S-EPMC12716101 | biostudies-literature | 2025 May

REPOSITORIES: biostudies-literature